Cryptococcosis Market Business Overview, Industry Insights, Top company analysis and Forecast by 2026 Cryptococcosis, also known as cryptococcal disease, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus neoformans and Cryptococcus gattii.
Request Free sample copy of report here @ https://www.qandqmarketresearch.com/report-sample/734548
The global Cryptococcosis market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.This report focuses on Cryptococcosis volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cryptococcosis market size by analyzing historical data and future prospect. The global cryptococcosis market is segmented into the key regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the leading share on the global cryptococcosis market for 2015, due to the rising prevalence of the infection in endemic areas of the U.S., coupled with a higher penetration of health care services across the country. The region is projected to continue to dominate the global cryptococcosis market till 2024, a fact attributed to the rising numbers of the HIV infected population in the region, a highly structured and advanced health care industry, and well-defined reimbursement policies from public as well as private health insurance firms. The following manufacturers are covered: Bristol-Myers Squibb Johnson & Johnson Abbott Novartis Pfizer Valeant Pharmaceuticals
